Brokerage firm Craig-Hallum Upgrades its rating on EXACT Sciences Corporation(NASDAQ:EXAS). The shares have been rated Buy. Previously, the analysts had a Hold rating on the shares. The rating by Craig-Hallum was issued on Jun 16, 2016.
In a different note, On May 4, 2016, Mizuho Securities said it Downgrades its rating on EXACT Sciences Corporation. The shares have been rated ‘Neutral’ by the firm.
EXACT Sciences Corporation (EXAS) shares turned negative on Tuesdays trading session with the shares closing down -0.85 points or -7.84% at a volume of 63,75,605. The pessimistic mood was evident in the company shares which never went considerably beyond the level of $10.91. The peak price level was also seen at $10.91 while the days lowest was $9.91. Finally the shares closed at $9.99. The 52-week high of the shares is $32.85 while the 52-week low is $4.67. According to the latest information available, the market cap of the company is $977 M.
EXACT Sciences Corporation(EXAS) last announced its earnings results on May 3, 2016 for Fiscal Year 2016 and Q1.Company reported revenue of $14.84M. Analysts had an estimated revenue of $14.83M. Earnings per share were $-0.49. Analysts had estimated an EPS of $-0.52.
Several Insider Transactions has been reported to the SEC. On Apr 4, 2016, D Scott Coward (SVP and General Counsel) sold 1,685 shares at $6.62 per share price.Also, On Mar 11, 2016, Maneesh Arora (COO) sold 4,042 shares at $6.05 per share price.On Mar 11, 2016, Graham Peter Lidgard (Chief Science Officer) sold 3,041 shares at $6.05 per share price, according to the Form-4 filing with the securities and exchange commission.
Exact Sciences Corporation is a molecular diagnostics company focused on the early detection and prevention of colorectal cancer. The Company has developed a non?invasive screening test called Cologuard for colorectal cancer. Its Cologuard test is a non?invasive stool?based deoxyribonucleic acid (DNA) (sDNA) screening test designed to detect DNA markers. In addition to DNA markers its test includes a protein marker to detect blood in the stool utilizing an antibody?based fecal immunochemical test (FIT). The Company’s Cologuard test is designed to detect pre?cancerous lesions or polyps and each of the four stages of colorectal cancer. By detecting pre?cancers and cancers early with its test affected patients can be referred to colonoscopy during which the polyps or lesions can be removed. The company’s test also detects blood in stool utilizing an antibody based FIT test.